Payment overview · 2025
General Payments
$1,838.48
78 reported records · 16 companies
Healthcare provider profile · identity verified
Rodrigo T. Samodal, MD
Allopathic & Osteopathic Physicians|Family Medicine · HORSEHEADS, NY · NPI 1710951249
Verified facts
What the public records show
CMS Open Payments records show Rodrigo T. Samodal, MD received $1,838.48 in general payments during 2025 across 78 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $487.27 | 26.5% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $420.36 | 22.9% | 17 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $195.49 | 10.6% | 12 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $156.05 | 8.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $130.08 | 7.1% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $92.11 | 5.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $91.12 | 5.0% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $54.35 | 3.0% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $42.39 | 2.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $40.23 | 2.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.42 | 2.0% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $22.89 | 1.2% | 1 | 2025 |
| PhotoniCare Inc | Unresolved — no canonical attribution shown | $22.61 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.03 | 0.9% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $15.15 | 0.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.93 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,838.48 | 78 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $395.38 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $334.77 | 12 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $195.49 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $176.03 | 8 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $156.05 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $148.18 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $114.86 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $92.11 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $91.12 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $75.06 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $51.85 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $42.39 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $40.23 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.63 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.63 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| OtoSight Middle Ear Scope Normalized: otosight middle ear scope |
Device | PhotoniCare Inc | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 148 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
148 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 841 | 221 |
| Levothyroxine Sodium | Levothyroxine Sodium | 601 | 150 |
| Amlodipine Besylate | Amlodipine Besylate | 521 | 134 |
| Lisinopril | Lisinopril | 511 | 137 |
| Gabapentin | Gabapentin | 384 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 372 | 105 |
| Omeprazole | Omeprazole | 362 | 98 |
| Losartan Potassium | Losartan Potassium | 319 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 299 | 76 |
| Metformin Hcl | Metformin Hcl | 298 | 85 |
| Furosemide | Furosemide | 288 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 271 | 68 |
| Trazodone Hcl | Trazodone Hcl | 271 | 82 |
| Escitalopram Oxalate | Escitalopram Oxalate | 269 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 245 | 66 |
| Pioglitazone Hcl | Pioglitazone Hcl | 239 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 238 | 51 |
| Simvastatin | Simvastatin | 220 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 196 | 48 |
| Montelukast Sodium | Montelukast Sodium | 192 | 53 |
| Diclofenac Sodium | Diclofenac Sodium | 171 | 51 |
| Eliquis | Apixaban | 171 | 33 |
| Fenofibrate | Fenofibrate Nanocrystallized | 169 | 41 |
| Potassium Chloride | Potassium Chloride | 169 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 166 | 65 |
| Carvedilol | Carvedilol | 163 | 35 |
| Alprazolam | Alprazolam | 160 | 34 |
| Buspirone Hcl | Buspirone Hcl | 154 | 50 |
| Donepezil Hcl | Donepezil Hcl | 153 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 149 | 40 |
| Farxiga | Dapagliflozin Propanediol | 148 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 144 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 34 |
| Metformin Hcl Er | Metformin Hcl | 138 | 45 |
| Sertraline Hcl | Sertraline Hcl | 133 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 27 |
| Bupropion Xl | Bupropion Hcl | 111 | 32 |
| Alendronate Sodium | Alendronate Sodium | 108 | 20 |
| Jardiance | Empagliflozin | 107 | 23 |
| Famotidine | Famotidine | 106 | 24 |
| Pregabalin | Pregabalin | 103 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 100 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 25 |
| Allopurinol | Allopurinol | 95 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 13 |
| Celecoxib | Celecoxib | 92 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 91 | 18 |
| Finasteride | Finasteride | 89 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 89 | 25 |
| Prednisone | Prednisone | 89 | 57 |
| Glipizide | Glipizide | 86 | 27 |
| Meloxicam | Meloxicam | 84 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 35 |
| Ezetimibe | Ezetimibe | 81 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 78 | 23 |
| Lorazepam | Lorazepam | 76 | 38 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 18 |
| Spironolactone | Spironolactone | 73 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 16 |
| Ozempic | Semaglutide | 71 | 22 |
| Mirtazapine | Mirtazapine | 70 | 14 |
| Tramadol Hcl | Tramadol Hcl | 70 | 32 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 69 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 67 | 11 |
| Januvia | Sitagliptin Phosphate | 65 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 19 |
| Novolog Flexpen | Insulin Aspart | 58 | suppressed |
| Clonazepam | Clonazepam | 57 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 20 |
| Propranolol Hcl | Propranolol Hcl | 55 | 11 |
| Atenolol | Atenolol | 54 | 14 |
| Glimepiride | Glimepiride | 52 | 16 |
| Myrbetriq | Mirabegron | 52 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 17 |
| Topiramate | Topiramate | 48 | 13 |
| Lovastatin | Lovastatin | 47 | suppressed |
| Memantine Hcl | Memantine Hcl | 47 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 46 | suppressed |
| Methotrexate | Methotrexate Sodium | 45 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | suppressed |
| Glipizide Er | Glipizide | 41 | 12 |
| Bumetanide | Bumetanide | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 37 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 36 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 36 | 24 |
| Ibuprofen | Ibuprofen | 35 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Torsemide | Torsemide | 34 | 13 |
| Aripiprazole | Aripiprazole | 33 | 14 |
| Olanzapine | Olanzapine | 33 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 33 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 31 | suppressed |
| Nystatin | Nystatin | 31 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 26 |
| Fluconazole | Fluconazole | 30 | 24 |
| Ramipril | Ramipril | 30 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 26 |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 28 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | 11 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | 13 |
| Lidocaine Hcl | Lidocaine Hcl | 22 | 15 |
| Folic Acid | Folic Acid | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 20 |
| Repaglinide | Repaglinide | 21 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Azithromycin | Azithromycin | 20 | 19 |
| Ceftriaxone | Ceftriaxone Sodium | 20 | 16 |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 13 |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Metronidazole | Metronidazole | 15 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 14 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lamotrigine Er | Lamotrigine | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,838.48 · 78 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BENLYSTA, BREZTRI, CAPLYTA, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, IBSRELA, KRYSTEXXA, MOUNJARO, OTEZLA, OtoSight Middle Ear Scope, Ozempic, REPATHA, REXULTI, Rybelsus, SAPHNELO, TRELEGY ELLIPTA, TREMFYA, VIBERZI, VRAYLAR, Wegovy, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error